Improvement in Esophageal Dysmotility in Systemic Sclerosis Following Anti-CD20 Therapy.

Rituxan (rituximab) - Roche

Improvement in Esophageal Dysmotility in Systemic Sclerosis Following Anti-CD20 Therapy. (PubMed, Int J Rheum Dis) - Oct 11, 2026 - No abstract available
Journal • Gastrointestinal Disorder • Immunology • Scleroderma • Systemic Sclerosis

http://www.ncbi.nlm.nih.gov/pubmed/42858334

Shintaro Hirata; Tomohiro Sugimoto; Yuji Shigemasa

Oct 11, 2026